RESEARCH & DEVELOPMENT
OVERVIEW
Vyera's research and development resources are aimed at developing novel therapies to treat serious diseases that have been neglected, such as toxoplasmosis and other parasitic infections. Vyera has completed early-stage studies to investigate the safety of VYR-006*, a novel molecule discovered and developed internally, for the treatment of toxoplasmosis.
*The safety and efficacy of the investigational products has not been established by health authorities or approved for use in the United States or globally.